Previous studies have shown that downregulation of key NER proteins, such as ERCC1, can increase the sensitivity of cancer cells to chemotherapeutic agents, including CDDP and mitomycin C, suggesting that targeting NER components could improve chemotherapy efficacy. Here, NR1H2 is linked to cancer.